Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.
Topics being addressed by individual working groups include:
The Biomarkers Task Force will reconvene in 2018 to lead a two-day workshop on critical next steps in the field, including:
This workshop will last two days and be held back-to-back with a two-day workshop from the Cancer Immune Responsiveness Task Force in May 2018. Participants are welcome to attend all four days of presentations and break-out session discussions.
Stay tuned in 2018 for dates, location and registration information to be shared by SITC.
In the video below, published by OncLive, watch as SITC President Dr. Lisa Butterfield, PhD discusses the Immune Biomarkers Task Force.
View current and past Task Force members via the links below:
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic Evaluation of Immune Regulation and Modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Taskforce Journal of Translational Medicine, December 2010
A Systematic Approach to Biomarker Discovery; Preamble to "the iSBTc-FDA Taskforce on Immunotherapy Biomarkers" Journal of Translational Medicine, December 2008
NCI/CCR and SITC co-sponsored a 2016 Biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017. Click here to read Immunotherapy Biomarkers 2016: Overcoming the Barriers. Also, to learn more about the event and its schedule, click here.
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. But cytotoxic chemotherapy can also destroy actively proliferating ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita Axelrod, MD; Stephanie Bork, MSN, CRNP; Nathaniel R. Evans III, ...
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor having experience with this treatment I would be eager to hear ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com